CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Temozolomidedrug
Likely dose
Temozolomide 100 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00575887
NCT00575887Phase 2Completed
CompareCT.gov

Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas

Marmara University·interventional·Posted Dec 18, 2007·Updated Dec 20, 2013

In Brief

A Phase 2 clinical trial evaluating Temozolomide for Glioblastoma and 3 related conditions. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma, Astrocytoma, Oligodendroglioma, Brain Tumor, Recurrent
CountriesTurkey (Türkiye)
CollaboratorsSchering-Plough

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 18, 2007
Enrollment StartAug 1, 2006
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.5 years ago

Interventions

Temozolomidedrug

100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity